We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




AI Model Detects Cancer at Lightning Speed through Sugar Analyses

By LabMedica International staff writers
Posted on 04 Jul 2024

Glycans, which are structures made up of sugar molecules within cells, can be analyzed using mass spectrometry. More...

This technique is particularly useful because these sugar structures can reveal the presence of various cancer types within cells. However, interpreting the data from mass spectrometry, specifically, the fragmentation patterns of glycans, requires meticulous human analysis. This detailed scrutiny can take from several hours to days per sample and is only reliably performed by a handful of highly skilled experts globally, as it involves complex, learned detective work over many years. This need for expert analysis creates a significant bottleneck in utilizing glycan analysis for applications like cancer detection, especially when numerous samples need examination. Researchers have now introduced an artificial intelligence (AI) model that enhances the ability to detect cancer through sugar molecule analysis, proving to be both quicker and more effective than the traditional semi-manual approaches.

The AI model, named Candycrunch, was trained by researchers at the University of Gothenburg (Gothenburg, Sweden) using a vast database containing over 500,000 examples of various fragmentations and associated structures of sugar molecules. This extensive training has equipped Candycrunch to accurately determine the precise structure of sugars in a sample in 90% of cases, aiming to soon match the accuracy levels seen in the sequencing of other biological sequences like DNA, RNA, and proteins. The AI model described in a scientific article published in Nature Methods automates glycan analysis and completes it in just a few seconds. Moreover, Candycrunch can identify sugar structures that are typically overlooked by human analysts due to their low concentrations. Due to its speed and precision, Candycrunch significantly speeds up the identification of glycan-based biomarkers, which are crucial for diagnosing and predicting cancer. Thus, the model holds promise in aiding researchers to discover new glycan-based biomarkers for cancer.

“We believe that glycan analyses will become a bigger part of biological and clinical research now that we have automated the biggest bottleneck,” said Daniel Bojar, Associate Senior Lecturer in Bioinformatics at the University of Gothenburg.

Related Links:
University of Gothenburg


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
New
Rapid Test Reader
DIA5000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The VeraBIND Tau assay is a novel blood test that identifies the presence of active tau pathology (Photo courtesy of 123RF)

First Blood-Based Test Measures Key Alzheimer's Biomarker in Asymptomatic and Symptomatic Individuals

Alzheimer’s disease (AD), the sixth leading cause of death in the United States, affects an estimated 7.2 million Americans aged 65 or older. Current diagnostic methods for AD are often invasive, expensive,... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The 3D paper-based analytical device has shown high clinical accuracy for adult-onset immunodeficiency (Photo courtesy of National Taiwan University)

Paper-Based Device Accurately Detects Immune Defects in 10 Minutes

Patients with hidden immune defects are especially vulnerable to severe and persistent infections, often due to autoantibodies that block interferon-gamma (IFN-γ), a key molecule in immune defense.... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.